The cost of vision for vitreoretinal interventions

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


PURPOSE OF REVIEW: This article reviews the current status of treatments for age-related macular degeneration from a cost-effectiveness perspective. RECENT FINDINGS: Treatments are now available to a broad range of patients with age-related macular degeneration, but they are pharmaceutical based and require repeated evaluation and treatment. The resulting unprecedented levels of cost make cost-effectiveness considerations more prescient. Newer methods to evaluate cost-effectiveness and treatment outcomes have included utility and value-based analyses. These have attempted to utilize accurate, objective parameters, but are calibrated by subjective patient assessments and are limited by certain methodological assumptions. Treatment methods to improve outcomes are increasingly being considered within the context of cost-effectiveness. SUMMARY: Although improved understanding of basic, cellular processes has led to markedly improved treatment options for age-related macular degeneration within the past decade, the high costs and wide applicability threaten the balance and viability of the payor system. Accurate means of assessing cost-effectiveness are critical to defining clinical applications.

Original languageEnglish (US)
Pages (from-to)195-201
Number of pages7
JournalCurrent opinion in ophthalmology
Issue number3
StatePublished - May 2008


  • Cost utility
  • Cost-effectiveness
  • Vitreoretinal surgery

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'The cost of vision for vitreoretinal interventions'. Together they form a unique fingerprint.

Cite this